

Benjamin D Powers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8463967/publications.pdf>

Version: 2024-02-01

31
papers

482
citations

759233

12
h-index

713466

21
g-index

31
all docs

31
docs citations

31
times ranked

601
citing authors

#	ARTICLE	IF	CITATIONS
1	MotPS is the stator-force generator for motility of alkaliphilic Bacillus, and its homologue is a second functional Mot in Bacillus subtilis. <i>Molecular Microbiology</i> , 2004, 53, 1035-1049.	2.5	100
2	Examining Rectal Carcinoids in the Era of Screening Colonoscopy. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 952-959.	1.3	52
3	The Impact of Socioeconomic Deprivation on Clinical Outcomes for Pancreatic Adenocarcinoma at a High-volume Cancer Center. <i>Annals of Surgery</i> , 2021, 274, e564-e573.	4.2	32
4	An Intergenic Stem-Loop Mutation in the Bacillus subtilis ccpA-motPS Operon Increases motPS Transcription and the MotPS Contribution to Motility. <i>Journal of Bacteriology</i> , 2006, 188, 2701-2705.	2.2	28
5	Readmissions After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a US HIPEC Collaborative Study. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 165-176.	1.7	26
6	Impact of Neoadjuvant Chemotherapy on the Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Multi-Institutional Retrospective Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 748.	2.4	22
7	Racial and ethnic disparities in a state-wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor to observed inequities. <i>Cancer Medicine</i> , 2019, 8, 3314-3324.	2.8	21
8	A Survival Analysis of Patients with Localized, Asymptomatic Pancreatic Neuroendocrine Tumors: No Surgical Survival Benefit when Examining Appropriately Selected Outcomes. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 2773-2779.	1.7	18
9	Adaptive Gene Expression in Bacillus subtilis Strains Deleted for tetL. <i>Journal of Bacteriology</i> , 2006, 188, 7090-7100.	2.2	16
10	Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative. <i>Annals of Surgical Oncology</i> , 2020, 27, 4980-4995.	1.5	15
11	A multi-institutional analysis of Textbook Outcomes among patients undergoing cytoreductive surgery for peritoneal surface malignancies. <i>Surgical Oncology</i> , 2021, 37, 101492.	1.6	15
12	Demographic risk factors impacting timely radiation therapy completion after breast conserving surgery. <i>American Journal of Surgery</i> , 2015, 210, 891-895.	1.8	14
13	What is the Optimal Preoperative Imaging Modality for Assessing Peritoneal Cancer Index? An Analysis From the United States HIPEC Collaborative. <i>Clinical Colorectal Cancer</i> , 2020, 19, e1-e7.	2.3	14
14	Development and Validation of an Explainable Machine Learning Model for Major Complications After Cytoreductive Surgery. <i>JAMA Network Open</i> , 2022, 5, e2212930.	5.9	13
15	Considerations in Testing for Inherited Breast Cancer Predisposition in the Era of Personalized Medicine. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 1-22.	1.5	12
16	The Intersection of Age and Tumor Biology with Postoperative Outcomes in Patients After Cytoreductive Surgery and HIPEC. <i>Annals of Surgical Oncology</i> , 2020, 27, 4894-4907.	1.5	11
17	Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Is Not Associated with Prohibitive Complications: Results of a Multiinstitutional Retrospective Study. <i>Annals of Surgical Oncology</i> , 2020, 27, 4883-4891.	1.5	11
18	Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways. <i>Journal of Surgical Oncology</i> , 2020, 122, 980-985.	1.7	10

#	ARTICLE	IF	CITATIONS
19	Impact of Perioperative Blood Transfusions on Outcomes After Hyperthermic Intraperitoneal Chemotherapy: A Propensity-Matched Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 4499-4507.	1.5	10
20	CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative. <i>Annals of Surgical Oncology</i> , 2020, 27, 4996-5004.	1.5	8
21	Cancer outcomes are independent of preoperative CA 19â€9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis. <i>Journal of Surgical Oncology</i> , 2020, 122, 1074-1083.	1.7	6
22	Patient Risk Subgroups Predict Benefit of Adjuvant Chemotherapy in Stage II Rectal Cancer Patients Following Neoadjuvant Chemoradiation and Total Mesorectal Excision. <i>Clinical Colorectal Cancer</i> , 2021, 20, e155-e164.	2.3	6
23	Preoperative Radiographic Assessment Predicts Incomplete Cytoreduction in Patients with Low Grade Mucinous Adenocarcinoma of the Appendix. <i>Annals of Surgical Oncology</i> , 2020, 27, 165-170.	1.5	5
24	The Impact of Histologic Subtype on Receipt of Adjuvant Chemotherapy and Overall Survival in Stage III Colon Cancer: a Retrospective Cohort Analysis. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 719-727.	1.3	4
25	A novel preoperative risk score to optimize patient selection for performing concomitant liver resection with cytoreductive surgery/HIPEC. <i>Journal of Surgical Oncology</i> , 2021, 123, 187-195.	1.7	4
26	The Utility of Preoperative Tumor Markers in Peritoneal Carcinomatosis from Primary Appendiceal Adenocarcinoma: an Analysis from the US HIPEC Collaborative. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2908-2919.	1.7	4
27	Integrating a Disease-Focused Tumor Board as a Delivery-of-Care Model to Expedite Treatment Initiation for Patients With Liver Malignancies. <i>Annals of Surgical Oncology</i> , 2022, 29, 2371-2380.	1.5	4
28	Pilot trial of remote monitoring to prevent malnutrition after hepatopancreatobiliary surgery. <i>BMC Nutrition</i> , 2021, 7, 82.	1.6	1
29	ASO Author Reflections: To Redo or Not to Redo, That is the Question: Assessing the Slings and Arrows of Repeat CRS/HIPEC in Patients with Recurrent or Progressive Peritoneal Carcinomatosis. <i>Annals of Surgical Oncology</i> , 2020, 27, 4892-4893.	1.5	0
30	The impact of census-tract socioeconomic status on survival in stage III colon cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7032-7032.	1.6	0
31	An intersectional investigation of race and sex on receipt of adjuvant chemotherapy in stage III colon cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 86-86.	1.6	0